MYL News and Press, Mylan N.V. From 04/08/20

Mylan N.V. ( MYL +5.7% ) announces that its production of malaria med hydroxychloroquine sulfate at its Morgantown, WV site has advanced ahead of schedule and has enabled the supply of additional product earlier than expected for COVID-19 patients. More news on: Mylan N.V., Healthcare ...

HERTFORDSHIRE, England and PITTSBURGH , April 8, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) Chairman Robert J. Coury and Chief Executive Officer Heather Bresch today provided additional detail regarding the company's continued commitment to meet public health needs amid the evolv...

Bristol-Myers Squibb ( BMY ) has been on a roller coaster ride in March 2020. The stock was not spared in the COVID-19 selloff, as shares toppled from $66.55 on February 6 all the way down to $48.00 on March 20. Although the stock has recovered and closed at $55.53 on April 3, BMY still rema...

The following slide deck was published by Mylan N.V. in conjunction with their 2019 Q4 earnings Read more ...

States across the U.S. are instituting measures to prevent hoarding of malaria drugs hydroxychloroquine and chloroquine in an effort to maintain supply amid acute demand from pharmacies and COVID-19 patients. More news on: Tekla World Healthcare Fund, BlackRock Health Sciences Trust, The...

Sanofi (NASDAQ: SNY) CEO Paul Hudson said that his company is ready, willing and able to produce a drug that seems to be efficacious in treating COVID-19, the disease that can result from the rapidly spreading SARS-CoV-2 coronavirus. In an interview with Reuters published Thursday, Hud...

Chloroquine and hydroxychloroquine aren't approved by the Food and Drug Administration to treat COVID-19, the disease caused by the novel coronavirus, but the agency has granted an emergency-use authorization for the drugs, which were originally developed to treat malaria. In Europe however...

The Food and Drug Administration has requested that Sanofi (NASDAQ: SNY) recall all of its Zantac heartburn products because the agency found that the amount of N-Nitrosodimethylamine (NDMA) in those products increases over time and when they are stored at higher than room temperatures. Whil...

The FDA is requesting all manufacturers of ranitidine drugs to withdraw them immediately from the U.S. market due to the presence of an impurity called N-Nitrosodimethylamine (NDMA), a suspected carcinogen. More news on: GlaxoSmithKline plc, Amneal Pharmaceuticals, Inc., Mylan N.V., Heal...

In a note, UBS regards the republished results from one of the first randomized trials evaluating malaria drug hydroxychloroquine (HCQ) in COVID-19 patients as "inconclusive." More news on: Tekla World Healthcare Fund, BlackRock Health Sciences Trust, The Gabelli Healthcare & Well...